MENU
JUN 17, 2020 1:30 PM PDT

Harnessing the power of synthetic biology to combat COVID-19

Sponsored by: Codex DNA
Speakers
  • CTO
    Biography
      Dan Gibson is the CTO of Codex DNA. He oversees Codex DNA's world-class R&D team and sets the technical vision for the company. Dan is the inventor of the Gibson Assembly® method, which has over 4,000 citations in scientific literature, and is regarded as a luminary in the field of synthetic biology. He and his team are consistently pioneering new ways to advance the field of synthetic biology and pushing boundaries in the disciplines of personalized medicine, antibody therapy development, agriculture and industrial materials. Dan and his team formed the foundational technology that drives the BioXp 3200TM and the Digital to Biologic Converter (DBC) and continue to develop new, cutting edge tools for whole genome design, synthesis and assembly, and activation. To learn more about the work of Dan's team and the DBC view his 2018 Ted talk. Prior to Codex, Dan was Vice President of DNA Technology at Synthetic Genomics where he spearheaded efforts to develop a rapid approach for producing viral genes used in pandemic vaccine production in 2013, and he led the team that developed the first synthesized minimal cell in the world in 2016. Prior to Synthetic Genomics Dan spent more than six years at the J. Craig Ventner Institute where he co-led the team that constructed the first synthetic bacterial genome in 2008 and the first synthetic cell in 2010. Dr. Gibson earned his Ph.D. in Molecular Biology from the University of Southern California. Before earning his Ph.D., he earned his Bachelor's degree in Biological Sciences from the State University of New York at Buffalo.
    • Staff Scientist
      Biography
        Krishna Kannan is a Staff Scientist at Codex DNA. He received his PhD from the University of Illinois at Chicago. Over the past few years, Krishna has worked closely with Synthetic Biology experts at JCVI and SGI, and contributed to the development of synthetic cell with a minimal genome and the digital-to-biological converter. He recently completed the de novo synthesis of the SARS-CoV-2 genome. Krishna's research has been published in top tier journals such as PNAS, Cell, Science and Nature Biotechnology. In his current role, Krishna is involved in Codex DNA's new product development.
      • Sr. Scientist
        Biography
          Katie Lyons is a molecular and synthetic biologist at Codex DNA. She was responsible for adapting the synthetic gene assembly process onto the BioXpTM , the first instrument capable of "printing" genes. Katie has worked in protein and RNA vaccine engineering, molecular diagnostics at the San Diego Zoo Institute for Conservation Research and is currently a Senior Scientist at Codex DNA.

        Abstract

        In his 2018 TED talk “How to build synthetic DNA and send it across the internet,” Dr. Dan Gibson highlighted a unique synthetic biology approach for fighting pandemics such as SARS, H1N1, and Ebola. Two years later, the unmitigated threat of COVID-19 has affected more than 2 million people to date and is expected to impact millions more.

        The current outbreak demands innovative synthetic biology solutions to develop vaccines, diagnostics, and treatments. Moreover, the identified number of genome variants of SARS-CoV-2 thus far is likely to impact future efforts towards the prevention, detection, and treatment of the disease. Solutions are needed to rapidly construct the SARS-CoV-2 genome, genome variants, genome parts, and vaccine / therapeutic scaffolds to treat and prevent current and future strains of the virus.

        Join us as we discuss our approach to completing the world’s first on-demand synthesis of the SARS-CoV-2 genome using a commercially available, automated DNA assembly and cloning instrument — the BioXp™ 3200 system. This solution accelerates vaccine, diagnostic, and treatment development pipelines by enabling rapid synthesis of up to 32 individual gene fragments in a single overnight run. We will also discuss the hierarchical assembly of the full-length SARS-CoV-2 genome and its potential applications.


        Show Resources
        You May Also Like
        JUN 17, 2020 1:30 PM PDT
        C.E. CREDITS
        JUN 17, 2020 1:30 PM PDT
        Understanding the complex interplay between a pathogen and the host response is important to developing effective vaccines and therapeutics. The nCounter® Analysis System and GeoMx®...
        APR 07, 2020 8:00 AM PDT
        C.E. CREDITS
        APR 07, 2020 8:00 AM PDT
        DATE: April 7, 2020 TIME: 8:00am PT, 11:00am ET This webinar sets out to establish why quality control is key to robust, reliable, reproducible science. We will look at best practice criteri...
        MAY 08, 2020 10:00 AM PDT
        C.E. CREDITS
        MAY 08, 2020 10:00 AM PDT
        DATE: May 8, 2020 TIME: 10:00am PT, 11:00am MT, 1:00pm ET The application of next generation sequencing to interrogate immune repertoires and methods in which these highly complex dataset...
        FEB 26, 2020 9:00 AM PST
        C.E. CREDITS
        FEB 26, 2020 9:00 AM PST
        DATE: February 26, 2020 TIME: 9:00am PST 3D cell culture and analysis and the study of organoids and spheroids are becoming more prevalent as a research method in publications as traditional...
        JUN 23, 2020 10:00 AM PDT
        C.E. CREDITS
        JUN 23, 2020 10:00 AM PDT
        DATE: June 23, 2020 TIME: 10:00am PT Human mesenchymal stromal or stem cells (MSCs)-based immunomodulation treatment has been proposed as a suitable therapeutic approach for many diseases, s...
        JUN 17, 2020 12:00 PM PDT
        C.E. CREDITS
        JUN 17, 2020 12:00 PM PDT
        The 2020 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to rage. While PCR-based assays are used for viral diagnosis, high through-put, rapid s...
        Loading Comments...
        Show Resources
        Attendees
        • See more